Encephalitis in Australia, 1979–2006: trends and aetiologies
DOI:
https://doi.org/10.33321/cdi.2009.33.18Keywords:
encephalitis, viral encephalitis, infectious encephalitis, Australia, emerging infectious diseaseAbstract
The acute encephalitis syndrome has heralded the emergence of multiple virulent pathogens, including Murray Valley encephalitis, Hendra virus and Australian bat lyssavirus, which may result in severe morbidity and mortality. In Australia, encephalitis is not notifiable and there has been no analysis of trends in encephalitis death rates or causation. Australian Bureau of Statistics mortality and population data for the period 1979–2006 were obtained and cause of death data were extracted using ICD-9 (1979–1998) and ICD-10 (1999–2006) codes that included all relevant encephalitis related diagnoses. Encephalitis-associated deaths were analysed by cause, year, age and gender. Between 1979 and 2006 there were 1,118 encephalitis-associated deaths in Australia. The average annual death rate was 2.3 per 1 million population (range 1.3–3.6). There was a significant decline in encephalitis-associated deaths, particularly due to 'known' pathogens (4.3% decline per year, 95%CI 3.1–5.4%, P<0.0001). The aetiology of 576 deaths were unknown and the proportion of deaths due to 'unknown' encephalitis increased from 47.0% between 1979 and 1992, to 57.2% from 1993 to 2006. Downward trends in encephalitis deaths due to 'known' causes can largely be explained by changes in treatment and prevention methods, particularly for herpes encephalitis (use of acyclovir), and measles encephalitis and subacute sclerosing panencephalitis (measles vaccination). The high proportion of encephalitis deaths from 'unknown' pathogens in Australia highlights the importance of monitoring encephalitis morbidity and mortality with a view to improving pathogen diagnosis and identifying emerging infectious diseases. Commun Dis Intell 2009;33:192–197.
Downloads
References
Chaudhuri A, Kennedy PG. Diagnosis and treatment of viral encephalitis. Postgrad Med J 2002;78:575–583.
Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. Lancet 2002;359:507–513.
Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, et al. Viral encephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol 2005;12:331–343.
Whitley RJ. Viral encephalitis. N Engl J Med 1990;323:242–250.
Whitley RJ. Herpes simplex virus infections of the central nervous system. A review. Am J Med 1988;85:61–67.
Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995;20:414–420.
Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986;314:144–149.
Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991;324:444–449.
Levitz RE. Herpes simplex encephalitis: a review. Heart Lung 1998;27:209–212.
Wutzler P. Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology 1997;40:343–356.
Noah DL, Drenzek CL, Smith JS, Krebs JW, Orciari L, Shaddock J, et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998;128:922–930.
Davison KL, Crowcroft NS, Ramsay ME, Brown DW, Andrews NJ. Viral encephalitis in England, 1989–1998: what did we miss? Emerg Infect Dis 2003;9:234–240.
Glaser CA, Honarmand S, Anderson LJ, Schnurr DP, Forghani B, Cossen CK, et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis 2006;43:1565–1577.
Khetsuriani N, Holman RC, Anderson LJ. Burden of encephalitis-associated hospitalizations in the United States, 1988–1997. Clin Infect Dis 2002;35:175–182.
Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. Nature 2008;451:990–993.
Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002;2:519–529.
Bellini WJ, Harcourt BH, Bowden N, Rota PA. Nipah virus: an emergent paramyxovirus causing severe encephalitis in humans. J Neurovirol 2005;11:481–487.
Speare R, Skerratt L, Foster R, Berger L, Hooper P, Lunt R, et al. Australian bat lyssavirus infection in three fruit bats from north Queensland. Commun Dis Intell 1997;21:117–120.
Barclay AJ, Paton DJ. Hendra (equine morbillivirus). Vet J 2000;160:169–176.
Khetsuriani N, Holman RC, Lamonte-Fowlkes AC, Selik RM, Anderson LJ. Trends in encephalitis-associated deaths in the United States. Epidemiol Infect 2007;135:583–591.
Rantalaiho T, Farkkila M, Vaheri A, Koskiniemi M. Acute encephalitis from 1967 to 1991. J Neurol Sci 2001;184:169–177.
Tilford JM, Roberson PK, Lensing S, Fiser DH. Differences in pediatric ICU mortality risk over time. Crit Care Med 1998;26:1737–1743.
Taylor A, Butt W, Ciardulli M. The functional outcome and quality of life of children after admission to an intensive care unit. Intensive Care Med 2003;29:795–800.
Taylor R, Lewis M, Powles J. The Australian mortality decline: cause-specific mortality 1907–1990. Aust N Z J Public Health 1998;22:37–44.
Victorian Drug Usage Advisory Committee. Antibiotic Guidelines. 5th ed. Melbourne, Victoria, Australia: Victorian Medical Postgraduate Foundation Therapeutics Committee; 1987.
Turnbull FM, Burgess MA, McIntyre PB, Lambert SB, Gilbert GL, Gidding HF, et al. The Australian Measles Control Campaign, 1998. Bull World Health Organ 2001;79:882–888.
Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J 2002;78:63–70.
Wong EH, Hui AC, Mok VC, Leung H, Chan RC, Wong KS, et al. A young man who kept falling over. Lancet 2008;372:418.
Solomon T. Exotic and emerging viral encephalitides. Curr Opin Neurol 2003;16:411–418.
Downloads
Published
How to Cite
License
Copyright (c) 2009 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
